Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 14/20 | 0.53 |
| ▸ | ITGB1 | P05556 | 13/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5176265 | 0.95 | ITGB1 (0.47) | ITGA4ITGB1MEN1KMT2AKDM1A | |
| SCHEMBL5414832 | 0.95 | ITGB1 (0.51) | ITGA4ITGB1MEN1KMT2AKDM1A | |
| SCHEMBL5176045 | 0.90 | ITGB1 (0.45) | ITGA4ITGB1MEN1KMT2AKDM1A | |
| SCHEMBL5158301 | 0.89 | ITGB1 (0.50) | ITGA4ITGB1MEN1KMT2AKDM1A | |
| SCHEMBL5159935 | 0.88 | ITGA4 (0.52) | ITGA4ITGB1MEN1KMT2AKDM1A | |
| SCHEMBL5158240 | 0.84 | ITGB1 (0.48) | ITGA4ITGB1MEN1KMT2AKDM1A | |
| SCHEMBL5163401 | 0.83 | ITGB1 (0.44) | ITGA4ITGB1MEN1KMT2AKDM1A | |
| SCHEMBL5176268 | 0.83 | ITGB1 (0.49) | ITGA4ITGB1MEN1KMT2AKDM1A | |
| SCHEMBL5163502 | 0.83 | ITGB1 (0.50) | ITGA4ITGB1MEN1KMT2AKDM1A | |
| SCHEMBL14608671 | 0.80 | ITGA4 (0.61) | ITGA4ITGB1MEN1KMT2AKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070232601-A1 | Vla-4 Inhibitor | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-10-04 | — | — | US | disclosed |
| EP-1757602-A1 | VLA-4 INHIBITOR | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232601-A1 | Vla-4 Inhibitor | VCAM1, ITGB4, ITGA4 | ITGA4 3/4885ITGB1 9/4885MEN1 711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.